Hyperfine, Inc.
No SEC Form 4 filings for $HYPR in the last 30 days.
See all $HYPR insider activity →Hyperfine (HYPR) reported preliminary Q3 revenue of $6.0M, exceeding the consensus estimate of $5.13M. This marks a 53% sequential increase from Q2 2026. The company's shares rose nearly 9% in pre-market trading.
Hyperfine, Inc. (HYPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to $22 Million Preliminary Revenue Represents 53% Sequential Quarterly Growth; Company Reaffirms 2026 Financial Gu
Hyperfine, Inc. (HYPR) generates 83.4% of revenue from DEVICE sales, with a gross margin of 50.72% but negative operating and net margins. It competes with SKIN and ECOR, with a market cap of $88.36M. Investors assess its performance in the Advanced Medical Equipment & Technology industry.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning HYPR (Hyperfine, Inc.). Coverage has skewed bullish: 4 bullish, 1 neutral, and 0 bearish.
Recent HYPR coverage spans earnings, insider activity and financial news.
Guidance beat and pre‑market rally suggest short‑term upside.
Hyperfine reported record preliminary Q3 revenue of $6M and reaffirmed FY2026 revenue guidance of $20‑22M, indicating strong sequential growth and improved cash burn.
New financial metrics may affect valuation models and investor sentiment.
Earnings call provides fresh operating datapoints (revenue, margins, cash burn) plus FY2026 guidance and clinical/labeling milestones that can re-rate near-term growth and funding needs.
The 8-K provides fresh quarterly datapoints plus full-year revenue and cash-burn guidance, which can drive near-term estimate revisions and positioning.
AlphAI scores every news story that mentions HYPR with an AI model for sentiment and relevance, and aggregates insider trades from Hyperfine, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Hyperfine (HYPR) reported preliminary Q3 revenue of $6.0M, exceeding the consensus estimate of $5.13M. This marks a 53% sequential increase from Q2 2026. The company's shares rose nearly 9% in pre-market trading.
1 min readHyperfine, Inc. (HYPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to $22 Million Preliminary Revenue Represents 53% Sequential Quarterly Growth; Company Reaffirms 2026 Financial Gu
2 min readHyperfine, Inc. (HYPR) generates 83.4% of revenue from DEVICE sales, with a gross margin of 50.72% but negative operating and net margins. It competes with SKIN and ECOR, with a market cap of $88.36M. Investors assess its performance in the Advanced Medical Equipment & Technology industry.
2 min readHyperfine (HYPR) reported Q2 2026 revenue of $3.9 million, up 45% year over year, and first-half revenue of $7.8 million, up 62%. Gross margin was 50.7%. Net loss was $9.3 million. Cash was $43.5 million at June 30, 2026. Full-year 2026 guidance: revenue $20-$22 million, gross margin 50%-55%, cash burn $26-$28 million.
7 min readHyperfine, Inc. (HYPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hyperfine, Inc. Reports Second Quarter 2026 Financial Results GUILFORD, Connecticut, August 6, 2026 (GLOBE NEWSWIRE) – Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered
6 min readHyperfine (Nasdaq: HYPR) says it has started launching its next-generation Swoop portable MRI system (Model 2) in Europe after CE mark and UKCA approval. The company also reports Model 2 inclusion in UniHA’s procurement listing for France’s public hospitals and plans broader European availability via distribution partners in 2026.
3 min readHALE BRETT (CFO and CAO) sold 6,047 shares of Hyperfine, Inc. (HYPR) at $1.65 on 2026-05-26.
1 min readTEISSEYRE THOMAS (Chief Operating Officer) sold 6,047 shares of Hyperfine, Inc. (HYPR) at $1.65 on 2026-05-26.
1 min readHyperfine, Inc. (NASDAQ:HYPR) has amended its at-the-market (ATM) issuance sales agreement to include BTIG, LLC as an additional sales agent alongside B. Riley Securities, Inc. This allows Hyperfine to offer and sell up to $50 million of its Class A common stock at its discretion. The company also terminated a previous prospectus supplement under which it had already sold shares for approximately $4.35 million.
2 min readHyperfine (HYPR) delivered earnings and revenue surprises of -10.00% and +1.09%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
2 min read
